UK markets closed

Addex Therapeutics Ltd (0QNV.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.0763-0.1807 (-70.31%)
At close: 04:57PM GMT

Addex Therapeutics Ltd

Chemin des Mines, 9
Geneva 1202
41 22 884 1555

Full-time employees24

Key executives

NameTitlePayExercisedYear born
Mr. Timothy Mark DyerCo-Founder, CEO & DirectorN/AN/A1968
Dr. Roger G. Mills M.D.Chief Medical Officer & DirectorN/AN/A1957
Mr. Lénaic TeyssédouHead of FinanceN/AN/A1986
Dr. Jean-Philippe Rocher Ph.D.Head of Discovery - ChemistryN/AN/A1959
Dr. Robert LutjensHead of Discovery - BiologyN/AN/A1968
Dr. Mikhail Kalinichev Ph.D.Head of Translational ScienceN/AN/A1967
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for pain, anxiety, and addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Corporate governance

Addex Therapeutics Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.